




The relative strengths and weaknesses of Spyre Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spyre Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 159% points. The greatest weakness of Spyre Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 344%, being 130% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	608,474
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	54,060
Liabilities, Non-Current	0
Other Assets	10
Other Compr. Net Income	-122
Other Expenses	51
Other Liabilities	36,620
Other Net Income	599
Other Revenues	0
Property and Equipment	0
Research and Development	162,790
Selling, General and Administrative Expense	45,776

Output Variable	Value in 1000 USD
Assets	608,484
Liabilities	90,680
Expenses	208,617
Revenues	0
Stockholders Equity	517,804
Net Income	-208,018
Comprehensive Net Income	-208,079
BaseVar	454,251
ECR before Limited Liability	263%
Economic Capital Ratio	344%